Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD)

Neuroscience Letters

Volumn 494, Issue 1, 2011, Pages 44-48

  Caballero, Miguel ^a   Núñez, Fabiana ^a   Ahern, Siobhán ^a   Cuffí, Maria L ^a   Carbonell, Lourdes ^a   Sánchez, Silvia ^a   Fernández Dueñas, Víctor ^a   Ciruela, Francisco ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adenosine receptors; ADHD; Caffeine

Indexed keywords

CAFFEINE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; FEMALE; MALE; MOTOR ACTIVITY; NEWBORN; NEWBORN CARE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 79953065395     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.02.050     Document Type: Article

References (36)

1. Arnold L.E., Christopher J., Huestis R., Smeltzer D.J. Methylphenidate vs. dextroamphetamine vs. caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis. Arch. Gen. Psychiatry 1978, 35:463-473.
2. Banaschewski T., Coghill D., Santosh P., Zuddas A., Asherson P., Buitelaar J., Danckaerts M., Dopfner M., Faraone S.V., Rothenberger A., Sergeant J., Steinhausen H.C., Sonuga-Barke E.J., Taylor E. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur. Child Adolesc. Psychiatry 2006, 15:476-495.
3. Biederman J., Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248.
4. Ciruela F., Franco R., Burgueño J. Medicines for attention deficit/hyperactivity disorder (ADHD). Pharmacology: targets of drug action in ADHD. Antidepressants, Antipsychotics, Anxiolytics: from Chemistry and Pharmacology to Clinical Application 2007, vol. 2:1155-1182. Wiley-VCH, Weinheim.
5. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010, 20(Suppl. 1):S95-S116.
6. Davids E., Zhang K., Tarazi F.I., Baldessarini R.J. Animal models of attention-deficit hyperactivity disorder. Brain Res. Brain Res. Rev. 2003, 42:1-21.
7. Dow-Edwards D.L., Weedon J.C., Hellmann E. Methylphenidate improves performance on the radial arm maze in periadolescent rats. Neurotoxicol. Teratol. 2008, 30:419-427.
8. Ferre S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casado V., Hillion J., Torvinen M., Fanelli F., Benedetti Pd P., Goldberg S.R., Bouvier M., Fuxe K., Agnati L.F., Lluis C., Franco R., Woods A. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 2004, 10:265-271.
9. Fuxe K., Marcellino D., Borroto-Escuela D.O., Guescini M., Fernandez-Duenas V., Tanganelli S., Rivera A., Ciruela F., Agnati L.F. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:e18-42.
10. Fuxe K., Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 1974, 52:48-54.
11. Huestis R.D., Arnold L.E., Smeltzer D.J. Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison. Am. J. Psychiatry 1975, 132:868-870.
12. Justinova Z., Ferre S., Barnes C., Wertheim C.E., Pappas L.A., Goldberg S.R., Le Foll B. Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. Psychopharmacology (Berl.) 2009, 203:355-367.
13. Kostrzewa R.M., Brus R., Kalbfleisch J.H., Perry K.W., Fuller R.W. Proposed animal model of attention deficit hyperactivity disorder. Brain Res. Bull. 1994, 34:161-167.
14. Kostrzewa R.M., Kostrzewa J.P., Kostrzewa R.A., Nowak P., Brus R. Pharmacological models of ADHD. J. Neural. Transm. 2008, 115:287-298.
15. Lindvall O., Bjorklund A. Anatomy of the dopaminergic neuron systems in the rat brain. Adv. Biochem. Psychopharmacol. 1978, 19:1-23.
16. Luthman J., Fredriksson A., Sundstrom E., Jonsson G., Archer T. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav. Brain Res. 1989, 33:267-277.
17. Nehlig A. Are we dependent upon coffee and caffeine? A review on human and animal data. Neurosci. Biobehav. Rev. 1999, 23:563-576.
18. Nehlig A. Is caffeine a cognitive enhancer?. J. Alzheimers Dis. 2010, 20(Suppl. 1):S85-S94.
19. Olton D.S., Collison C., Werz M.A. Spatial memory and radial arm maze performance of rats. Learn. Behav. 1977, 8:289-314.
20. Olton D.S., Werz M.A. Hippocampal function and behavior: spatial discrimination and response inhibition. Physiol. Behav. 1978, 20:597-605.
21. Paxinos G., Tork I., Tecott L.H., Valentino K.L. Atlas of the Developing Rat Brain 1991, Academic Press, San Diego, p. 144.
22. Perez-Gracia E., Torrejon-Escribano B., Ferrer I. Dystrophic neurites of senile plaques in Alzheimer's disease are deficient in cytochrome c oxidase. Acta Neuropathol. 2008, 116:261-268.
23. Pires V.A., Pamplona F.A., Pandolfo P., Prediger R.D., Takahashi R.N. Chronic caffeine treatment during prepubertal period confers long-term cognitive benefits in adult spontaneously hypertensive rats (SHR), an animal model of attention deficit hyperactivity disorder (ADHD). Behav. Brain Res. 2010, 215:39-44.
24. Prediger R.D., Pamplona F.A., Fernandes D., Takahashi R.N. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) - the spontaneously hypertensive rat (SHR). Int. J. Neuropsychopharmacol. 2005, 8:583-594.
25. Roberts W.A. Spatial memory in the rat on a hierarchical maze. Learn. Behav. 1979, 10:117-140.
26. Roeloffs C., Bartlik B., Kaplan P.M., Kocsis J.H. Methylphenidate and SSRI-induced sexual side effects. J. Clin. Psychiatry 1996, 57:548.
27. Sagvolden T., Russell V.A., Aase H., Johansen E.B., Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1239-1247.
28. Salvatore M.F., Pruett B.S., Spann S.L., Dempsey C. Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS One 2009, 4:e8466.
29. Shaywitz B.A., Klopper J.H., Yager R.D., Gordon J.W. Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature 1976, 261:153-155.
30. Shaywitz B.A., Yager R.D., Klopper J.H. Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science 1976, 191:305-308.
31. Sonuga-Barke E.J., Coghill D., Wigal T., DeBacker M., Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J. Child Adolesc. Psychopharmacol. 2009, 19:683-690.
32. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
33. Takahashi R.N., Pamplona F.A., Prediger R.D. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci. 2008, 13:2614-2632.
34. van der Kooij M.A., Glennon J.C. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 2007, 31:597-618.
35. Wammanda R.D. Hyperactivity and inattention - a successful response to table coffee. Niger. J. Clin. Pract. 2007, 10:182-183.
36. Zhang K., Tarazi F.I., Baldessarini R.J. Role of dopamine D(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology 2001, 25:624-632.